GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Omnicell Inc (NAS:OMCL) » Definitions » EBIT

Omnicell (Omnicell) EBIT : $-34 Mil (TTM As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Omnicell EBIT?

Omnicell's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-22 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-34 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Omnicell's annualized ROC % for the quarter that ended in Mar. 2024 was -4.74%. Omnicell's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -41.68%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Omnicell's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -2.29%.


Omnicell EBIT Historical Data

The historical data trend for Omnicell's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omnicell EBIT Chart

Omnicell Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 78.35 35.53 89.51 -2.32 -34.87

Omnicell Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.96 7.75 3.71 -23.37 -21.85

Competitive Comparison of Omnicell's EBIT

For the Health Information Services subindustry, Omnicell's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omnicell's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Omnicell's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Omnicell's EV-to-EBIT falls into.



Omnicell EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Omnicell  (NAS:OMCL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Omnicell's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-87.388 * ( 1 - 12.09% )/( (1617.453 + 1626.378)/ 2 )
=-76.8227908/1621.9155
=-4.74 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2226.878 - 129.586 - ( 479.839 - max(0, 367.792 - 927.571+479.839))
=1617.453

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2283.755 - 132.976 - ( 524.401 - max(0, 416.364 - 989.918+524.401))
=1626.378

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Omnicell's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-87.388/( ( (133.589 + max(90.458, 0)) + (135.565 + max(59.702, 0)) )/ 2 )
=-87.388/( ( 224.047 + 195.267 )/ 2 )
=-87.388/209.657
=-41.68 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(252.025 + 110.099 + 85.608) - (129.586 + 175.934 + 51.754)
=90.458

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(248.512 + 103.466 + 113.539) - (132.976 + 231.393 + 41.446)
=59.702

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Omnicell's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-33.752/1474.371
=-2.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Omnicell EBIT Related Terms

Thank you for viewing the detailed overview of Omnicell's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Omnicell (Omnicell) Business Description

Traded in Other Exchanges
Address
2625 Augustine Drive, Suite 301, Santa Clara, CA, USA, 95054
Omnicell Inc provides automation and business analytics software for healthcare providers. The automation and analytics segment manufactures medication dispensing systems, pharmacy inventory management systems, and related software. The medication adherence segment sells products like consumable medication blister cards and packaging equipment to help administer medication outside of a hospital setting. Omnicell generates the vast majority of its revenue in the United States.
Executives
Kaushik Ghoshal director 9001 SPECTRUM CENTER BLVD, SAN DIEGO CA 92123
Christine Marie Mellon officer: EVP, Chief People Officer 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Randall A Lipps director, officer: President and CEO 1101 EAST MEADOW DR, PALO ALTO CA 94303
Nchacha Etta officer: EVP & CFO 4220 NORTH FREEWAY, FORT WORTH TX 76137
Joanne B Bauer director 1400 HOLCOMB BRIDGE ROAD, ROSWELL GA 30076-2199
Scott Peter Seidelmann officer: EVP, Chief Commercial Officer 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Peter J. Kuipers officer: Executive V.P. CFO 590 E. MIDDLEFEILD ROAD, MOUNTAIN VIEW CA 94043
Mary Garrett director ETHAN ALLEN DRIVE, DANBURY CT 06811
Manley Corey J officer: SR. VP & CHIEF LEGAL OFFICER 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Dan S Johnston officer: V.P., Legal & General Counsel
Joseph Brian Spears officer: Chief Accounting Officer & VP 590 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
James T Judson officer: VP Finance & Acting CFO C/O OMNICELL, INC., 1201 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043
Robin Gene Seim officer: V.P., Finance & CFO 1201 CHARLESTON ROAD, MOUNTAIN VIEW CA 94043
Edward Peter Bousa director 280 CONGRESS STREET, BOSTON MA 02210
Nhat H Ngo officer: VP, Strategy & Business Dev. 490 NORTH WIGET LANE, WALNUT CREEK CA 94598